Core Viewpoint - The company, 美丽田园医疗健康 (02373), has announced a plan to enhance shareholder value by potentially utilizing up to HKD 1.2 billion over the next three years through dividends and share buybacks [1] Group 1: Shareholder Returns - The board has resolved to provide returns to shareholders via two main methods: (i) declaring annual dividends according to the current dividend policy, with a commitment to distribute no less than 50% of the net profit attributable to shareholders each year for the next three full financial years [1] - The second method involves share buybacks, which will be conducted under a general mandate granted at the upcoming annual general meeting on June 27, 2025, following the expiration of the current buyback authorization [1] Group 2: Financial Impact - The company plans to fund these initiatives through internal resources and expects that the implementation of these plans will not have a significant adverse impact on the group's working capital position [1] - As of the date of the announcement, the company has been authorized to repurchase 23,579,556 shares and has already repurchased a total of 605,500 shares under the existing buyback authorization [1]

Group 1 - The company, 美丽田园医疗健康 (02373), has announced a plan to enhance shareholder value by potentially utilizing up to HKD 1.2 billion over the next three years [1] - The company will provide returns to shareholders through two main methods: (i) declaring annual dividends based on the current dividend policy, with a commitment to distribute no less than 50% of the net profit attributable to shareholders each year for the next three fiscal years [1] - Alternatively, the company may repurchase its shares in the market, subject to general authorization granted at the upcoming annual general meeting [1] Group 2 - The funding for these plans will be sourced from the company's internal resources, and it is expected that the implementation will not significantly adversely affect the group's working capital [1] - The company has been authorized to repurchase a total of 23,579,556 shares under the existing buyback authorization, and as of the announcement date, it has repurchased a total of 605,500 shares [1]

美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 內幕消息 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 股東及本公司潛在投資者務請注意，上述計劃的實施由董事會全權決定，任何股息 宣派及股份購回安排將基於本集團經營業績及重大併購情況等作出，而任何股份的 購回則須視乎市場狀況及遵守適用規則與法規而定，故無法保證任何將予派發的股 息或將予進行的購回的時間、數量或價格。 股東及本公司潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 美麗田園醫療健康產業有限公司 主席兼執行董事 李陽 香港，2025年11月4日 長期股東回報計劃 美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集團」）謹此根 據香港法例第571章證券及期貨條例第XIVA部的內幕消息條文（定義見香港聯合交 易 ...

Core Viewpoint - On October 31, 33 Hong Kong-listed companies conducted share buybacks, totaling 21.84 million shares and an aggregate amount of HKD 152 million [1][2]. Group 1: Buyback Details - China COSCO Shipping Holdings (中远海控) repurchased 3 million shares for HKD 40.71 million, with a highest price of HKD 13.750 and a lowest price of HKD 13.350, bringing its total buyback amount for the year to HKD 4.447 billion [1][2]. - Guo Sheng Tang (固生堂) repurchased 582,000 shares for HKD 16.59 million, with a highest price of HKD 28.680 and a lowest price of HKD 28.340, totaling HKD 284 million in buybacks for the year [1][2]. - Sinopec Limited (中国石油化工股份) repurchased 3.652 million shares for HKD 15.12 million, with a highest price of HKD 4.170 and a lowest price of HKD 4.110, accumulating HKD 871 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 31 was from China COSCO Shipping Holdings at HKD 40.71 million, followed by Guo Sheng Tang at HKD 16.59 million [1][2]. - In terms of share quantity, Sinopec Limited led with 3.652 million shares repurchased, followed by China COSCO Shipping Holdings with 3 million shares and Linklogis Technology (联易融科技-W) with 2.34 million shares [1][2].

Core Viewpoint - Meili Tianyuan Healthcare (02373) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 40,000 shares at a total cost of HKD 1.2362 million [1] - The buyback price per share ranges from HKD 30.72 to HKD 31.06 [1] Financial Implications - The total expenditure for the share buyback reflects the company's strategy to enhance shareholder value [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 40,000 shares at a total cost of HKD 1.2362 million [1] - The buyback price per share ranges from HKD 30.72 to HKD 31.06 [1] Financial Implications - The total expenditure for the share buyback reflects the company's strategy to enhance shareholder value [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback of 40,000 shares at a cost of HKD 1.236 million on October 31 [1] Group 1 - The company executed a buyback program, indicating a potential strategy to enhance shareholder value [1] - The total expenditure for the buyback was HKD 1.236 million, reflecting the company's commitment to returning capital to shareholders [1] - The number of shares repurchased was 40,000, which may influence the stock's liquidity and market perception [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - The company repurchased 40,000 shares on October 31, 2025, for a total transaction amount of approximately HKD 1,236,230, with an average price of about HKD 30.91 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 515,000 shares at a total cost of approximately HKD 16,305,450 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2025年10月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 自願公告 市場股份回購 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 本公司欣然公佈，本公司於2025年10月31日於市場購回40,000股本公司股份，總交 易金額約1,236,230港元，交易平均價約每股30.91港元。自2025年10月15日至本公 告日期止期間，本公司已購回共515,000股股份，總對價約16,305,450港元。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 的堅定信心，有利於提升本集團資本市場價值及股東回報能力。 ...